Sugi Predict

Sugi Predict / Targets / FGFR1

FGFR1

Fibroblast growth factor receptor 1 · P11362 · FGFR1 on Sugi Atlas →

319,715 patent compounds predicted against FGFR1, 202,312 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL63471 SCHEMBL63471 0.64 15/20
Azd-4547 Azd-4547 (SCHEMBL62926) 0.75 12/20
Fexagratinib Fexagratinib (SCHEMBL63884) 0.75 12/20
Bilirubin Bilirubin (SCHEMBL19065) 0.38 12/20
Vandetanib Vandetanib (SCHEMBL9044) 1.00 11/20
SCHEMBL11295 SCHEMBL11295 0.65 11/20
SCHEMBL65188 SCHEMBL65188 0.65 11/20
SCHEMBL63000 SCHEMBL63000 0.64 11/20
SCHEMBL64317 SCHEMBL64317 0.64 11/20
SCHEMBL19506 SCHEMBL19506 0.53 11/20
SCHEMBL63624 SCHEMBL63624 0.65 10/20
SCHEMBL63195 SCHEMBL63195 0.64 10/20
SCHEMBL63470 SCHEMBL63470 0.58 10/20
Pha-665752 Pha-665752 (SCHEMBL93654) 1.00 9/20
Pha-665752 Pha-665752 (SCHEMBL93655) 1.00 9/20
SCHEMBL62356 SCHEMBL62356 0.59 9/20
SCHEMBL64219 SCHEMBL64219 0.52 9/20
SCHEMBL64186 SCHEMBL64186 0.51 9/20
SCHEMBL62562 SCHEMBL62562 0.82 8/20
SCHEMBL9280 SCHEMBL9280 0.77 8/20

Clinical trials — most relevant to FGFR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer PHASE2COMPLETED
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors PHASE2WITHDRAWN
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy PHASE2UNKNOWN
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations PHASE2COMPLETED
A Study of TAS-120 in Patients With Advanced Solid Tumors PHASE1/PHASE2COMPLETED
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma PHASE2COMPLETED
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling PHASE2WITHDRAWN
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens PHASE2COMPLETED
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 PHASE1/PHASE2RECRUITING
Study of Infigratinib in Children With Achondroplasia PHASE2COMPLETED
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration PHASE2COMPLETED
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations PHASE2WITHDRAWN
Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations PHASE2UNKNOWN
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma PHASE1/PHASE2COMPLETED
Expansion Trial for Axitinib In Head And Neck Cancer PHASE2COMPLETED
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations PHASE1/PHASE2WITHDRAWN
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma PHASE2WITHDRAWN
A Monotherapy in Subjects With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations PHASE1RECRUITING
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD） PHASE1RECRUITING
Phase 1 Study of E7090 in Subjects With Solid Tumor PHASE1COMPLETED
Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations PHASE1COMPLETED
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations PHASE1RECRUITING
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) PHASE1COMPLETED
Role of FGF21 in Breast Cancer nanNOT_YET_RECRUITING
Erdafitinib in Metastatic Steroid-cell Ovarian Cancer nanCOMPLETED
A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients nanUNKNOWN
External Body Weight Effects on Body Weight in Adults With Grade II and III Obesity nanNOT_YET_RECRUITING
Cardiovascular Effects of Empagliflozine nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a FGFR1 binder may also engage these)

ProteinNameSimilarity
Q04589 — 1.000 Q04589 →
Q91287 — 1.000 Q91287 →
P18461 — 1.000 P18461 →
Q90Z00 — 1.000 Q90Z00 →
Q91288 — 1.000 Q91288 →
FGFR3 Fibroblast growth factor receptor 3 1.000 landscape →
P21804 — 1.000 P21804 →
O42127 — 1.000 O42127 →
Q91147 — 0.999 Q91147 →
Q9I8X3 — 0.999 Q9I8X3 →
Q8JG38 — 0.998 Q8JG38 →
P16092 — 0.998 P16092 →
P18460 — 0.997 P18460 →
Q91743 — 0.997 Q91743 →
Q90330 — 0.997 Q90330 →
Q61851 — 0.996 Q61851 →
Q91285 — 0.995 Q91285 →
P22182 — 0.995 P22182 →
P21803 — 0.995 P21803 →
Q00495 — 0.993 Q00495 →
B4KPU0 — 0.992 B4KPU0 →
Q03364 — 0.991 Q03364 →
Q90413 — 0.991 Q90413 →
EPHA5 Ephrin type-A receptor 5 0.991 landscape →
Q91286 — 0.991 Q91286 →
A0JM20 — 0.990 A0JM20 →
MUSK Muscle, skeletal receptor tyrosine-protein kinase 0.990 landscape →
CSF1R Macrophage colony-stimulating factor 1 receptor 0.990 landscape →
Q9YI66 — 0.989 Q9YI66 →
Q4H3K6 — 0.988 Q4H3K6 →